<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving DTD v1.0 20120330//EN" "JATS-journalarchiving.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ali="http://www.niso.org/schemas/ali/1.0">
  <front>
    <article-meta>
      <title-group>
        <article-title>Diagnostic Performance of Ultra Sonography in Evaluation of Thyroid Nodule UsingATAThyroid Nodule Sonographic Patterns and Quantitative Doppler Parameters and Correlation with FNAC</article-title>
      </title-group>
      <abstract>
        <p id="_paragraph-1"><bold id="bold-1">Background: </bold>Thyroid nodule is common endocrine disease. FNAC is gold standard but not sensitive test. Ultrasonography features are known for risk stratification of thyroid nodule, and identifying which nodules can be triaged for repeat FNAC after negative FNA results as well. Many ultrasound risk stratification classifications of thyroid nodule are existing. But, none of these classification systems have been widely adopted worldwide due to their inherent limitations. Hence scientific data on USG thyroid needs updation to enhance the diagnostic performance of ultrasonography. <bold id="bold-2">Aims and Objectives: </bold>To assess the diagnostic performance of Grayscale sonography using ATA thyroid nodule sonographic patterns; and doppler sonography using spectral doppler parameters, i.e., RI and PI alone and in combination in determining benign and malignant thyroid nodule compared to gold standard FNAC. <bold id="bold-3">Materials and Methods: </bold>Prospective Observational Cross sectional diagnostic study. On all patients gray scale HRUS, Doppler sonography performed. Resistance Index (RI) and Pulsatility Index (PI) were assessed with spectral doppler technique. <bold id="bold-4">Results and Summary: </bold>In our study diagnostic performance of quantitative doppler parameters, i.c., RI and PI evaluated with ROC analysis revealed RI (AUC -0.813) is better predictor for malignancy than PI (AUC -0.788). An optimum cutoff of RI is&gt;0.67. with good sensitivity 73.7%, specificity 81.2%, PPV 60.90%, NPV 88.6% to distinguish malignant from benign lesion. <bold id="bold-5">Conclusion: </bold>In our study quantitative doppler parameter, i.c., RI alone showed higher diagnostic performance to distinguish malignant from benign lesion compared to gray scale sonography and combined gray scale and doppler sonography.</p>
      </abstract>
    </article-meta>
  </front>
  <body id="body">
    <sec id="heading-c226dfaafe5b271f87d1f6462d58a2fc">
      <title>Introduction</title>
      <p id="paragraph-1">Thyroid diseases are commonest endocrine disorder worldwide [1]. Various pathologies affect the gland are benign (colloid nodule, Hashimoto’s thyroiditis, simple or hemorrhagic cyst, follicular adenoma and subacute thyroiditis) and malignant (Papillary Cancer, Follicular Cancer, Hurthle Cell (oncocytic) Cancer, Anaplastic Cancer, Medullary Cancer, Thyroid Lymphoma and metastases [2]. Most common presentation of the many of the thyroid pathologies is goiter or nodule [2]. A discrete swelling(nodule) in one lobe with no palpable abnormality elsewhere is termed an isolated or solitary swelling. Discrete swellings with evidence of abnormality elsewhere in the gland are termed dominant. The importance of discrete swellings lies in the risk of neoplasia compared with other thyroid swellings. About 20% of isolated swellings prove to be malignant, about 30-40% are follicular adenomas. The remainder are non-neoplastic largely consisting of areas of colloid degeneration. Majority of the thyroid nodules are asymptomatic, incidentally discovered with various imaging procedures done for investigation of an unrelated condition. Incidental thyroid nodules are being diagnosed with increasing frequency in the recent years due to increased use of imaging [3-5]. Thyroid nodules are common, seen in about 8.5% of the population [3]. Thyroid nodule can be palpable or nonpalpable, solitary or dominant. Palpable thyroid nodules occur only in 4-7 percent population [3, 6]. Majority of the nodules are cystic in nature, and are hyperplastic nodules that have undergone liquefactive degeneration. The clinical importance of thyroid nodules is related to excluding malignancy (4.0 to 6.5% of all thyroid nodules), evaluate their functional status and assess for the presence of pressure symptoms [3]. Thyroid cancer incidence rates are increasing in high income countries [7]. Age standardised incidence rates of thyroid cancer Globally in 2020 as per Globocon database for 185 countries by sex and 18 age groups are 10.1 per 100 000 women and 3.1 per 100 000 men, highest noted in south korea, i.e., 45 per 100 000 [8]. Hence all the thyroid nodules &gt;1 cm need evaluation irrespective of palpability [3]. Nodules that are below 1 cm need to be evaluated based on individual risk [3]. The prognosis of thyroid cancer depend on the tumour type and its stage at the time of diagnosis [9, 10]. The prognosis for thyroid cancers such as PTC and FTC is excellent, since they are microscopic, indolent and are stable [2, 9, 10]. The 5-year relative survival is 98.6% overall, 99.9% for localized cancers, i.e., PTC and FTC [7]. Though the aggressive tumours such as MTC. DHGTC, PDTC, HGMTC are lethal require more intense treatment[11, 12]. the most thyroid cancer related deaths are from papillary, follicular, and Hürthle cell carcinomas since differentiated thyroid carcinomas represent more than 95% of all cases [11]. Hence, whenever a patient presents with a thyroid swelling, the task of the clinician is to distinguish the benign nodule from the malignant one. This is difficult task, and no test is perfect in this regard [3]. Various procedures in use to establish tissue diagnosis of lesions are fine needle aspiration cytology (FNAC), core needle biopsy (CNB), or excision biopsy and histopathology. FNAC is the first line diagnostic technique for thyroid nodules since decades. It is simple, safe, inexpensive, and has high diagnostic accuracy (97%). Limitations of the FNAC are cannot distinguish follicular carcinoma from follicular adenoma. Procedure related complication rates are high with CNB and excision biopsy and histopathology.</p>
      <p id="paragraph-db2a5f46cea1050600eb7c9652b9e5c0" />
      <sec id="heading-82e912c1a1f99582213411510b528b6d">
        <title>
          <italic id="italic-1">Aims and Objectives </italic>
        </title>
        <sec id="heading-f04db16cd6bbe6711229313f71e32638">
          <title>
            <italic id="italic_-5ad746a8ba12d3ecd44b1d87179bcf16">Aims</italic>
          </title>
          <p id="paragraph-3">To evaluate the diagnostic performance of Gray scale and Doppler sonography in determining benign and malignant thyroid nodule.</p>
          <p id="paragraph-4" />
        </sec>
        <sec id="heading-bea357ef162074f59d83851d51b93065">
          <title>
            <italic id="italic-2">Objectives<italic id="italic-3"/></italic>
          </title>
          <p id="paragraph-6">To assess the diagnostic performance of Grayscale sonography using ATA thyroid nodule sonographic patterns in determining benign and malignant thyroid nodule compared to gold standard FNAC.</p>
          <p id="paragraph-7">To assess the diagnostic performance of combined Grayscale and doppler sonography using ATA thyroid nodule sonographic patterns and spectral doppler parameters, i.e., RI and PI in determining malignant and benign thyroid nodules compared to gold standard FNAC.</p>
          <p id="paragraph-2" />
        </sec>
      </sec>
    </sec>
    <sec id="heading-1">
      <title>Materials and Methods</title>
      <p id="paragraph-997d04a0d3d299ad6aa3d5c863585ff3">Study design: Prospective Observational Cross sectional, Diagnostic accuracy study</p>
      <p id="paragraph-5">Location: Dept. of Radiology and Imageology, Nizam’s Institute of Medical Sciences.</p>
      <p id="paragraph-1e4dc33e319dd2fca42e1b436d3fb483">Period of recruitment: Nov 2020- June 2024 Participants:</p>
      <p id="paragraph-8">• All the patients &gt;17yrs age referred to radiology department with clinical suspicion of palpable or non- palpable thyroid lesions irrespective of sex.</p>
      <p id="paragraph-9">• Patients with incidentally detected thyroid nodules.</p>
      <p id="paragraph-10">• Ethics committee approval code.</p>
      <p id="paragraph-11">Nizams Institutional Ethics Committee Approval. Review Letter NO.EC/ NIMS/2715/2021</p>
      <p id="paragraph-12">ESGS NO. 1117/2021.</p>
      <p id="paragraph-13">Follow up: All the lesions were followed up with FNAC and Histo pathology examination.</p>
      <p id="paragraph-14">Data collection: Name, Age, Gender, Patient history, Clinical symptoms, Gray scale USG appearances, Doppler Sonography parameters, HPE diagnosis.</p>
      <p id="paragraph-15">Eligibility criteria:</p>
      <p id="paragraph-16">• All the patients &gt;17yrs age referred to radiology department with clinical suspicion of palpable or non- palpable thyroid lesions irrespective of sex and subsequent HPE.</p>
      <p id="paragraph-17">• Patients with incidentally detected thyroid nodules and subsequent HPE.</p>
      <p id="paragraph-19">• Patients who give written informed consent.</p>
      <p id="paragraph-20">Variables: Age, Gender, Gray scale sonography, Combined Gray scale +Doppler sonography, RI, PI,</p>
      <p id="paragraph-21">SPSS version-24 was used for statistical analysis.</p>
      <p id="paragraph-22">Statistical methods: Mean and SD were calculated for quantitative variables like Age, RI and PI.</p>
      <p id="paragraph-24">Frequencies and percentage are calculated for Age, gender, lesion,.</p>
      <p id="paragraph-25">t-test used for calculation of mean age of benign and mean age of malignant lesions; comparison of mean values of RI and PI.</p>
      <p id="paragraph-26">Chi square test was used to study the association between Age groups and type of lesion</p>
      <p id="paragraph-27">ROC curves used to generate best cut off value of RI and PI, and to estimate sensitivity, specificity and AUC to calculate the better predictor for malignancy.</p>
      <p id="paragraph-28">Sensitivity, Specificity, PPV, NPV, Accuracy, AUC were calculated for estimation of diagnostic performance of a test.</p>
      <p id="paragraph-29">P-value was considered as 0.05</p>
      <p id="paragraph-30">Chi-square used to compare the observed results with expected results, i.e., USG+DOPPLER results with HPE results. The kappa value suggests level of agreement between test and gold standard (in our study HPE).</p>
      <p id="paragraph-31" />
      <sec id="heading-21562419865cda3fd998134c4d206fb6">
        <title>
          <italic id="italic-45818192bda064f8626030826725e20a">Imaging Technique</italic>
        </title>
        <p id="paragraph-33">On all the patients gray scale HRUS, Doppler sonography performed with esaote My lab 9 ultrasound unit using a high frequency linear transducer (7.5 - 15 MHz), with use of various signal processing techniques, i.e. are Spatial compounding imaging, speckle reduction technique, Harmonic imaging technique. Speed of sound imaging, Extended field of view. Doppler sonography of nodules done with following machine setting - G.76% , High Pulse repetition frequency (PRF) 2.1KHz, wall filter (WF) usually 50Hz -100Hz and gate size involving the central 2/3 of vessel. Scan performed with patients lie in the supine position with the neck extended. A small pad is placed under the shoulders to provide better exposure of the thyroid gland. The thyroid gland is examined thoroughly in both transverse and longitudinal planes [13]. </p>
        <p id="paragraph-e82cf131a895fd659dfbbbfbaaed86b5" />
      </sec>
      <sec id="heading-2ed098ea779a8e15c36575f68c7918ee">
        <title>
          <italic id="italic-f875dcf30decbae3e65950f5a8f067f8">Image Analysis</italic>
        </title>
        <p id="paragraph-8ba7cdbf755f4c16bb9fd73080ac5fbc">Normal appearances of the gland: The normal thyroid gland is uniformly hyperechoic. Gray scale features used for assessment of nodule are: size, shape, margins, peripheral hypoechoic halo, composition, echogenicity, echogenic foci and calcifications [14, 15]. Doppler sonography features used for assessment are: Vascularity (central, peripheral), RI &amp; PI. all the lesions were categorized into benign and malignant according to ATA US classification. </p>
        <p id="paragraph-6c10e0a45f4f42ef2fd3024cdad4477f">Nodule composition is described as solid, cystic or mixed (if the cystic component occupied an area of less than 25%, it was considered as solid; between 25 and 74% as mixed; and 75 and 100% as cystic). The nodule borders are described as smooth or irregular. Shape of the nodules is described as taller than the width and wider than the depth. Calcifications are described as no calcification, microcalcifications (≤2 mm), peripheral rim calcifications (continuous vs discontinuous) and macrocalcifications (&gt; 2 mm). The peripheral halo is described as present or absent. Echogenicity is described as hypoechoic, hyperechoic, or mixed when compared to the normal thyroid parenchyma. Echogenic foci are described as hyperechoic foci with comet tail artefacts. Vascularity is described as peripheral, peripheral &amp; central, central central with associated peripheral vascular arc. Spectral doppler findings are described as RI value of ≥ 0.70 considered as increased likelihood of malignancy and RI &lt; 0.70 increased likelihood of benign. Similarly, the nodules which showed PI of ≥ 1.3 increased likelihood of malignancy and PI &lt; 1.3 as increased likelihood of benign. Ultrasound machine estimates the Resistive Index (RI) and pulsatility index (PI) values with use of inbuilt software.</p>
        <p id="paragraph-5e5bc7be4cab468bde947a38899354a0">ATA patterns of sonographic features and risk of malignancy [14].</p>
        <p id="paragraph-c4eaf81ca98ee0abd03bb2f8b4721ee6" />
        <p id="paragraph-e67fa2d16e4c738bcb7608f20b5cf02c">High suspicion [malignancy risk &gt;70%-90%]</p>
        <p id="paragraph-273c9cbbbf3b6ef06a4f6a39cac9af0a" />
        <p id="paragraph-6225c11e8bc7f7b6ce8e5e6ece86c0fb">Solid hypoechoic nodule or a solid hypoechoic component in a partially cystic nodule with one or more of the following features: irregular margins (specifically defined as infiltrative, micro-lobulated, or spiculated), microcalcifications, taller than wide shape, disrupted rim calcifications with small extrusive hypoechoic soft tissue component, or evidence of extrathyroidal extension. Consider FNA at &gt;/= to 1cm [16-20] (Figure 1).</p>
        <fig id="figure-panel-4fd59a6cabc34d665071302808678a1f">
          <label>Figure 1. ATA Thyroid Nodule Sonographic Pattern - High Suspicious for Malignancy. Pathological diagnosis was Malignancy – Bethesda V</label>
          <caption>
            <title></title>
            <p id="paragraph-6d24874feba5b073b8979eb7230fc49e" />
          </caption>
          <graphic id="graphic-c4e3eae61ca7ef351f32fb63ff24f4f0" mimetype="image" mime-subtype="jpeg" xlink:href="http://waocp.com/journal/fig/cn/APJCN_V1_i1_N43_2025_Fig_1.jpg" />
        </fig>
        <p id="paragraph-82d51ebdacf30ccf0fc7f82ff91eea55">Intermediate suspicion [malignancy risk 10% -20%]</p>
        <p id="paragraph-5f762b8387692d4097253b981401b76e" />
        <p id="paragraph-c50345cd353ac6a26c8512bb464f6d4e">Solid hypoechoic nodule with smooth irregular margin, but without micro-calcifications, extrathyroidal extension, or taller than wide shape. Consider FNA at &gt;/= to 1cm. (Figure 2 and Figure 3).</p>
        <fig id="figure-panel-779a986e2eb27af8bdd9ed2a5b452823">
          <label>Figure 2. ATA Thyroid Nodule Sonographic Pattern- Intermediate Suspicious Lesion. Pathological diagnosis Follicular neoplasm – Bethesda-IV </label>
          <caption>
            <title></title>
            <p id="paragraph-d46e918257f825f6ff3c8c15f7831d81" />
          </caption>
          <graphic id="graphic-46a3305c4a5c7a8d99556123b6d9a05a" mimetype="image" mime-subtype="jpeg" xlink:href="http://waocp.com/journal/fig/cn/APJCN_V1_i1_N43_2025_Fig_2.jpg" />
        </fig>
        <p id="paragraph-9df5261451ea62ec2728962fd62d8d58" />
        <fig id="figure-panel-e65fa61fada5468ec43a569a6918df55">
          <label>Figure 3. ATA Thyroid Nodule Sonographic Patterns Intermediate Suspicious Lesion. Pathological diagnosis Follicular lesion of unknown significance – Bethesda – III</label>
          <caption>
            <title></title>
            <p id="paragraph-425acc09885a6aaa53776b5aded09334" />
          </caption>
          <graphic id="graphic-d434558cff66ee0470e52c189698818c" mimetype="image" mime-subtype="jpeg" xlink:href="http://waocp.com/journal/fig/cn/APJCN_V1_i1_N43_2025_Fig_3.jpg" />
        </fig>
        <p id="paragraph-421825abe8564c4157bedb216267b142">Low suspicion [malignancy risk 5%-10%]</p>
        <p id="paragraph-3521ceaf7f1d03e2d31a7c4ca812b8e2" />
        <p id="paragraph-02911eb239ea0b4da1c72202fdf7db49">Isoechoic or hyperechoic solid nodule, or partially cystic nodule with eccentric uniformly solid areas without micro-calcifications, irregular margin, or extrathyroidal extension, or taller than wide shape. Consider FNA at &gt;/= to 1.5 cm (Figure 4).</p>
        <fig id="figure-panel-38788bfa10658dcc6f4ee482997202f8">
          <label>Figure 4. ATA Thyroid Nodule Sonographic Pattern - Low Suspicious for Malignancy. FNAC diagnosis - Adenomatous nodule - Bethesda II </label>
          <caption>
            <title></title>
            <p id="paragraph-74f6c2493f5630fe6d16d65bd043375a" />
          </caption>
          <graphic id="graphic-9aa62df29bf2cc22f7cb94af6b373223" mimetype="image" mime-subtype="jpeg" xlink:href="http://waocp.com/journal/fig/cn/APJCN_V1_i1_N43_2025_Fig_4.jpg" />
        </fig>
        <p id="paragraph-2901263c5b490c48695416b273990819"> Very low suspicion [&lt;3%]:</p>
        <p id="paragraph-1f4f585f0b1380f4739172aad3930e73" />
        <p id="paragraph-a2cb39102b90b98e3d55085e865ad0c3">Spongiform or partially cystic nodule without any of the sonographic features described in the low, intermediate, or high suspicion patterns. Consider FNA at &gt;/=2cm, observation without FNA is also a reasonable option (Figure 5 and Figure 6)</p>
        <fig id="figure-panel-7f09532518ad055677e9d75872eceb1c">
          <label>Figure 5. ATA Thyroid Nodule Sonographic Pattern - Low Suspicious. Pathological diagnosis - Adenomatous nodule - Bethesda – II</label>
          <caption>
            <title></title>
            <p id="paragraph-8f4ae50d26d599a86a9c4af37e44c980" />
          </caption>
          <graphic id="graphic-48ddde96f48a830b0a92eb759a4f41b7" mimetype="image" mime-subtype="jpeg" xlink:href="http://waocp.com/journal/fig/cn/APJCN_V1_i1_N43_2025_Fig_5.jpg" />
        </fig>
        <p id="paragraph-dd1e9098f8e3f254c789cb3c0e6dc5fa" />
        <fig id="figure-panel-fd1ad21152ec138ad81dd17dd181b49b">
          <label>Figure 6. ATA Thyroid Nodule Sonographic Patterns - Low Suspicious. Pathological diagnosis - Hashimoto’s thyroiditis – Bethesda II</label>
          <caption>
            <title></title>
            <p id="paragraph-79c17ff59997020ac9b3f5741c07a8e7" />
          </caption>
          <graphic id="graphic-99c0551ca548b1762174ae76d57acae3" mimetype="image" mime-subtype="jpeg" xlink:href="http://waocp.com/journal/fig/cn/APJCN_V1_i1_N43_2025_Fig_6.jpg" />
        </fig>
        <p id="paragraph-88613dbe05c39f89f1248af3c2250442">BENIGN [&lt; 1%]:</p>
        <p id="paragraph-1e85e2abe3d2ed01a83ed0eaf17d5fda" />
        <p id="paragraph-d7847d6c84a7897a89a21d2044af5fa5">Purely cystic nodules are very unlikely to be malignant. </p>
        <p id="paragraph-2e69118c42912d161b09f1621d5f49ab">No biopsy indicated [19, 20]. </p>
        <p id="paragraph-eebe4f2724da674a7658c29a9775c4d1">Inclusion Criteria: </p>
        <p id="paragraph-97d6a1a69a2861363a56d506f393bc4f">All the patients with palpable thyroid nodules with or without symptoms </p>
        <p id="paragraph-230296e4c2e9794634d3deac0267713a">Symptomatic patients with Non-palpable lesions detected on diagnostic ultrasound. </p>
        <p id="paragraph-f0cbf11d298c8bc738fa4a63325a7b3d">Patients with asymptomatic lesions incidentally detected on neck imaging for other indication. </p>
        <p id="paragraph-c59a0c48760ba0343f6503a8ed7e3d79">Exclusion Criteria: </p>
        <p id="paragraph-a6fd6e2ba6c4ac341a13128dea19bb0f">Cases undergoing treatment. </p>
        <p id="paragraph-c6a851283689dbc32e3995ccd1746b91">Cases received treatment and on follow up. </p>
        <p id="paragraph-42940895887e7bd6f2a9045f68347fc5">Patients without FNAC / HPE diagnosis. </p>
        <p id="paragraph-e912c0441fed7a48baee8a809fabe97d">Patients who are not willing to give informed consent.</p>
        <p id="paragraph-2905aabcf7ff29a4b26a2845ec14957a" />
      </sec>
    </sec>
    <sec id="heading-d41d10ab7f60dcc91fc1b4da861feef5">
      <title>Results</title>
      <sec id="heading-ffb8726e2a2457b9ad399e358984918b">
        <title>
          <italic id="italic-2ba66a0d98b6dd233b0679915272d9cf">Statistical Analysis</italic>
        </title>
        <p id="paragraph-7c5c0daf2eeefb9377335f5b9a979323">A total of 67 patients were included in our study. Out of 67 patients; females are 53 (79.1%), males are 14 (20.9%).</p>
        <p id="paragraph-d14349315e3bbb33ded58ff8b7ce8305">Out of 67 nodules, 48 (71.6%) are histopathology proven benign nodules, 19 (28.4%) are histopathology proven malignant nodules (Table 1). </p>
        <table-wrap id="table-figure-b0767322f54fc033a5e3110c6ec2ae9d">
          <label>Table 1. Showing Number of FNAC /HPE Proven Benign and Malignant Lesions</label>
          <caption>
            <title></title>
            <p id="paragraph-54a8394a60a016504878eabf20e97de5" />
          </caption>
          <table id="table-247b0218b730c186f05b3a11d51b5677">
            <tbody>
              <tr>
               <td>Lesion type</td>
               <td>No. of lesions</td>
               <td>Percent</td>
            </tr>
            <tr>
               <td>Benign</td>
               <td>48</td>
               <td>71.6</td>
            </tr>
            <tr>
               <td>Malignant</td>
               <td>19</td>
               <td>28.4</td>
            </tr>
            <tr>
               <td>Total</td>
               <td>67</td>
               <td>100</td>
            </tr>
            </tbody>
          </table>
        </table-wrap>
        <p id="paragraph-31408286ae4e62a71860ed105ce03371">Mean age was significantly (p&lt;0.001) higher in malignant (49.8±15.43) than Benign lesion (47.08±12.86) using ‘t’ test. Out of 48 benign nodules 39 (81%) nodules were in females; 9 (18.8%) nodules were in males. Out of 19 malignant nodules 14 (73.7%) nodules were in females; 5 (26.3%) nodules were in males (Table 4). Statistical analysis revealed there is no association between gender and lesion type (p=0.492). Among 67 patients; maximum number of patients 19 (28.40%) were in 41-50 years age group, followed by 31-40 years age group 17 (25.4%) (Table 2, Table 3, Table 4).</p>
        <table-wrap id="table-figure-78aef55a6d2d0ef8605929c2aba7ac3b">
          <label>Table 2. Lesion Frequency by Age and Gender</label>
          <caption>
            <title></title>
            <p id="paragraph-4c4ad4d42bfb8f6945ea4d2719dfc4fa" />
          </caption>
          <table id="table-3bd681926f126b10cdbc9bd724408e4a">
            <tbody>
               <tr>
               <td>Patient’s Age Group (in Years)</td>
               <td>M (%)</td>
               <td>F (%)</td>
               <td>Total</td>
               <td>Percentage</td>
            </tr>
            <tr>
               <td>21-30</td>
               <td>2 (33.33)</td>
               <td>4 (66.66)</td>
               <td>6</td>
               <td>9</td>
            </tr>
            <tr>
               <td>31-40</td>
               <td>2 (11.76)</td>
               <td>15 (88.24)</td>
               <td>17</td>
               <td>25.40</td>
            </tr>
            <tr>
               <td>41-50</td>
               <td>4 (21.05)</td>
               <td>15 (78.95)</td>
               <td>19</td>
               <td>28.40</td>
            </tr>
            <tr>
               <td>51-60</td>
               <td>3 (27.27)</td>
               <td>8 (72.72)</td>
               <td>11</td>
               <td>16.40</td>
            </tr>
            <tr>
               <td>61-70</td>
               <td>2 (18.18)</td>
               <td>9 (81.81)</td>
               <td>11</td>
               <td>16.40</td>
            </tr>
            <tr>
               <td>71-80</td>
               <td>1 (33.33)</td>
               <td>2 (66.66)</td>
               <td>3</td>
               <td>4.50</td>
            </tr>
            <tr>
               <td>Total</td>
               <td>14 (20.90)</td>
               <td>53 (79.10)</td>
               <td>67</td>
               <td>100</td>
            </tr>
            </tbody>
          </table>
        </table-wrap>
        <p id="paragraph-5561632955760847e1b4e4b2ad36d866"> Maximum number of lesions 19 (28.4%) noted in 41-50 years age group, followed by 31-40years 17 (25.4%). Lesion frequency is more in females in all age groups compared to males.</p>
        <p id="paragraph-5eee5f3304013130df6de34398fe5507" />
        <table-wrap id="table-figure-49c5acb50e64c24749764bc93b02f3e3">
          <label>Table 3. Frequency of Lesion Type by Age</label>
          <caption>
            <title></title>
            <p id="paragraph-f195eae1e1d1f6704caa40839bc537a2" />
          </caption>
          <table id="table-7992d094fe244a016009f91d09f7fc9b">
            <tbody>
              <tr>
               <td/>
               <td/>
               <td/>
               <td>             HPE</td>
               <td/>
               <td>Total</td>
            </tr>
            <tr>
               <td/>
               <td/>
               <td/>
               <td>Benign</td>
               <td>Malignant</td>
               <td/>
            </tr>
            <tr>
               <td>Age Group</td>
               <td>21-30</td>
               <td>Count</td>
               <td>4</td>
               <td>2</td>
               <td>6</td>
            </tr>
            <tr>
               <td/>
               <td/>
               <td>%</td>
               <td>66.66</td>
               <td>33.33</td>
               <td>9.00</td>
            </tr>
            <tr>
               <td/>
               <td>31-40</td>
               <td>Count</td>
               <td>14</td>
               <td>3</td>
               <td>17</td>
            </tr>
            <tr>
               <td/>
               <td/>
               <td>%</td>
               <td>82.35</td>
               <td>17.65</td>
               <td>25.40</td>
            </tr>
            <tr>
               <td/>
               <td>41-50</td>
               <td>Count</td>
               <td>13</td>
               <td>6</td>
               <td>19</td>
            </tr>
            <tr>
               <td/>
               <td/>
               <td>%</td>
               <td>68.42</td>
               <td>31.58</td>
               <td>28.40</td>
            </tr>
            <tr>
               <td/>
               <td>51-60</td>
               <td>Count</td>
               <td>8</td>
               <td>3</td>
               <td>11</td>
            </tr>
            <tr>
               <td/>
               <td/>
               <td>%</td>
               <td>72.72</td>
               <td>27.27</td>
               <td>16.40</td>
            </tr>
            <tr>
               <td/>
               <td>61-70</td>
               <td>Count</td>
               <td>7</td>
               <td>4</td>
               <td>11</td>
            </tr>
            <tr>
               <td/>
               <td/>
               <td>%</td>
               <td>63.63</td>
               <td>36.36</td>
               <td>16.40</td>
            </tr>
            <tr>
               <td/>
               <td>71-80</td>
               <td>Count</td>
               <td>2</td>
               <td>1</td>
               <td>3</td>
            </tr>
            <tr>
               <td/>
               <td/>
               <td>%</td>
               <td>66.66</td>
               <td>33.33</td>
               <td>4.50</td>
            </tr>
            <tr>
               <td>Total</td>
               <td/>
               <td>Count</td>
               <td>48</td>
               <td>19</td>
               <td>67</td>
            </tr>
            <tr>
               <td/>
               <td/>
               <td>%</td>
               <td>100.00</td>
               <td>100.00</td>
               <td>100.00</td>
            </tr>
            </tbody>
          </table>
        </table-wrap>
        <p id="paragraph-c463777207ff76cbae040dfd9f4fd275"> Benign lesions are more frequent in all age groups compared to malignant ones. Benign nodules more frequent (29.17%) in 31-40year age group. Malignant nodules are more frequent (36.36%) in 61-70 year age group. </p>
        <p id="paragraph-b61ba89b1d75630e2700367c7f5e5111" />
        <table-wrap id="table-figure-11ac1a2196df2f8265ac9805c3b224cf">
          <label>Table 4. Gender Distribution of Benign and Malignant Lesions</label>
          <caption>
            <title></title>
            <p id="paragraph-c5ecef853fd771cccc263a202a64e259" />
          </caption>
          <table id="table-f0f7b54f4f971fa71a954220ed22f89c">
            <tbody>
              <tr>
               <td/>
               <td/>
               <td/>
               <td>HPE</td>
               <td/>
               <td>Total</td>
            </tr>
            <tr>
               <td/>
               <td/>
               <td/>
               <td>Benign</td>
               <td>Malignant</td>
               <td/>
            </tr>
            <tr>
               <td>Sex</td>
               <td>Female</td>
               <td>Count</td>
               <td>39</td>
               <td>14</td>
               <td>53</td>
            </tr>
            <tr>
               <td/>
               <td/>
               <td>%</td>
               <td>81.30</td>
               <td>73.70</td>
               <td>79.10</td>
            </tr>
            <tr>
               <td/>
               <td>Male</td>
               <td>Count</td>
               <td>9</td>
               <td>5</td>
               <td>14</td>
            </tr>
            <tr>
               <td/>
               <td/>
               <td>%</td>
               <td>18.80</td>
               <td>26.30</td>
               <td>20.90</td>
            </tr>
            <tr>
               <td>Total</td>
               <td/>
               <td>Count</td>
               <td>48 (71.64%)</td>
               <td>19 (28.36%)</td>
               <td>67</td>
            </tr>
            </tbody>
          </table>
        </table-wrap>
        <p id="paragraph-85af43357fd28d94791de793e5df520c">Out of 48 benign nodules 39 (81%) nodules were in females; 9 (18.8%) nodules were in males. Out of 19 malignant nodules 14 (73.7%) nodules were in females; 5 (26.3%) nodules were in males.</p>
        <p id="paragraph-2bfbec56db7dc860ba6da6f3d111bf44" />
        <p id="paragraph-5ef54b2d7146e724836605a5480b048a">Statistical analysis revealed no Association between age group and lesion type (p=0.911) (Table 3) Association between age range and benign lesions is (25-77). Association between age range and malignant lesions is (21-71). In all age groups Benign lesions are more frequent compared to malignant ones (Table 3).</p>
        <p id="paragraph-6c8288999217220313caff6a6287612c">Cumulative percent of benign lesions is 71.6%. Benign nodules more frequent (29.17%) in 31-40year age group. Statistical analysis revealed no Association between age group and lesion type (p=0.911). Lesion frequency is more in female population in all age groups compared to males (Table 4). In our study evaluation of diagnostic performance of quantitative doppler parameters, i.e., RI and PI with ROC analysis revealed optimum cutoff of RI to determine malignant lesions is &gt;0.67 with sensitivity of 73.7%, specificity 81.2%, PPV 60.90%, NPV 88.6%.</p>
        <p id="paragraph-021bbdb27b43d0448b2650978b0e7359">Optimum cutoff of PI to determine malignant lesions is &gt;0.9 with sensitivity of 94.7%, specificity 60.4%, PPV 48.60%, NPV 96.70%. Both RI and PI show statistical significance (p-value&lt;0.0001). AUC calculation with ROC curve analysis revealed RI is better predictor for malignancy than PI since area under curve of RI is (AUC -0.813) is larger than PI (AUC -0.788). In our study evaluation of diagnostic performance of Grayscale sonography using ATA thyroid nodule sonographic patterns in determining benign Vs malignant thyroid nodules compared to gold standard FNAC /HPE revealed <underline id="underline-1">(Supplementary</underline><underline id="underline-2"> Table 1):</underline> Out of 67 nodules, 30 (44.78%) were benign, 37 (55.22%) were malignant. 26 (86.67%) out of 30 benign nodules showed correlation with FNAC. 15 (40.54%) out of 37 malignant nodules showed correlation with FNAC. Diagnostic test calculation revealed sensitivity (78.95%), specificity (54.17%), PPV (40.54%), NPV (86.66%), accuracy 61.19%. Evaluation of Diagnostic performance of combined Grayscale and Doppler sonography <underline id="underline-eb4f8e33d27e142d0bad26f6b2b11139">(Supplementary Table 1</underline>) in differentiating malignant from benign thyroid nodules using ATA thyroid nodule sonographic patterns and quantitative doppler parameter RI revealed: Out of 64 nodules 25 (37.31%) were benign, 42 (62.69%) were malignant. Out of 25 benign nodules 23 (92%) nodules showed correlation with HPE. Out of 42 malignant nodules 17 (40.48%) showed correlation with HPE with sensitivity 89.47%, specificity 47.92%, PPV40.48%, NPV92.00% with an accuracy of 59.70%.</p>
        <p id="paragraph-2fd028ce8722cce88915e95f25945fdb" />
      </sec>
    </sec>
    <sec id="heading-bd3d6dbbf1cf6f4e1720eae870d592dd">
      <title>Discussion</title>
      <p id="paragraph-905b9dd236e7b41f9d3b8637a7eb76c3">American thyroid association ATA patterns of sonographic features are complex but are evidence based recommendations which include initial evaluation of nodule, clinical and ultrasound criteria for fine-needle aspiration biopsy, interpretation of fine-needle aspiration biopsy results, use of molecular markers, and management of benign and malignant thyroid nodules. And major goal of ATA patterns of sonographic features is to minimize potential harm from over treatment in majority of patients at low risk for disease-specific mortality and morbidity, while appropriately treating and monitoring those patients at higher risk.</p>
      <p id="paragraph-b91ba3f4b499bc631025ae1a5d58116e">In our study evaluation of diagnostic performance of Gray scale sonography using ATA thyroid nodule sonographic patterns in determining benign Vs malignant thyroid nodules compared to gold standard FNAC / HPE revealed (Supplementary Table 1) revealed good sensitivity (78.95%), moderate specificity (54.17%), poor PPV (40.54%), good NPV (86.66%), accuracy 61.2% with fair agreement with gold standard (kappa-0.257) - No similar study found in published scientific data.</p>
      <p id="paragraph-88d23c1e78ae2a535dd1dc7744deef3e">In our study evaluation of diagnostic performance of quantitative doppler parameters RI, and PI in determining malignant Vs benign lesions with ROC curve analysis revealed optimum cut off of RI to determine malignant lesions is &gt;0.67 with sensitivity of 73.7%, specificity 81.2%. Optimum cut off of PI to determine malignant lesions is &gt;0.9 with sensitivity of 94.7%, specificity 60.4%. Both RI and PI show statistical significance (p-value&lt;0.0001). AUC of RI is larger (0.813) than the PI. hence, better predictor of lesion than PI.</p>
      <p id="paragraph-09eef79dda942e98e877cc302fef7f0a">Our study results are in concordance with study done by Saeed Kalantari, In their study on 63 patients concluded there is significant association between Resistive Index and Pulsatility Index with malignancy with a cutoff of RI ≥ 0.715 (P=0.005) and PI ≥ 0.945 (P=0.007) [21]. Manoj</p>
      <p id="paragraph-b0a58b9ecc1cb32402f3fb68d0752cda">Kumar Palaniappan et al. [22] In their study on 194 nodules revealed best cut off of RI greater than 0.73, best cut off of PI greater than 1.3 to differentiate malignant from benign. Sensitivity, and specificity of spectral doppler in differentiating benign vs malignant lesions revealed 76.78%, and 81.7% respectively.</p>
      <p id="paragraph-9b39314ceaae1c1e70b35f140d9884b9">Evaluation of diagnostic performance of combined Gray scale and Doppler sonography using ATA thyroid nodule sonographic patterns and quantitative doppler parameters (RI, PI): ATA+RI revealed good sensitivity (89.47%), poor specificity (47.92%), poor PPV (40.48%) and good NPV (92.00%), with diagnostic accuracy of 59.70% with fair agreement with gold standard Kappa= 0.274 (Supplementary Table 1). Compared to Gray scale sonography using ATA patterns of sonographic features there is mild increase in sensitivity at the cost of mild decrease in specificity with fair agreement with gold standard. No similar study found in published data.</p>
      <p id="paragraph-34bef5181d30c7a5ec3ae31494766fcb">In conclusion, in our study evaluation of diagnostic performance of quantitative doppler parameters RI, and PI in determining malignant Vs benign lesions with ROC curve analysis revealed RI is better predictor of lesion than PI (AUC of RI -0.813 larger than PI) with highest sensitivity. Specificity 73.7%, 81.2%.</p>
      <p id="paragraph-b168f223626353f1a74efeff11f934dc">Evaluation of diagnostic performance of combined Gray scale and Doppler sonography with use of ATA thyroid nodule sonographic patterns and quantitative doppler parameter, i.e., RI revealed No added advantage of doppler.</p>
      <p id="paragraph-97e9fd4b779a569f46a0c283e7a34b9d" />
      <p id="paragraph-6bf58c6a51e9bf7f8b30884601e8b4eb">
        <italic id="italic-ec16b5044a73524f91980770af9205d3">Limitations<italic id="italic-91ddf22369cdc2aea2b8c1c0cddb3f03"/></italic>
      </p>
      <p id="paragraph-25bf8690db85f0a3bd1a79e8e0651c0b">Doppler sonography is operator and machinery settings dependent.</p>
      <p id="paragraph-b1eda4d92ef100532cb204fd7f507ddb">Sample size is small and needs studies with larger data to validate our study result.</p>
      <p id="paragraph-3fc91f9e4d4b53b2850d04d57226fd69" />
    </sec>
    <sec id="heading-a8a1749e7f82385568ee036f91fead84">
      <title>Acknowledgments</title>
      <p id="paragraph-fbee5211a8a52b6ede885cba02411c44">
        <italic id="italic-9f4f02ffd697777bd4182d078f76d7fc">Statement of Transparency and Principals:</italic>
      </p>
      <p id="paragraph-b91828d0527eb1185a2a8e7b066f06f8">• Author declares no conflict of interest</p>
      <p id="paragraph-3ca71388e561e09d992751d3ef2d11ba">• Study was approved by Research Ethic Committee of author affiliated Institute.</p>
      <p id="paragraph-af567b83ded82ed3e2627e70ffefd469">• Study’s data is available upon a reasonable request.</p>
      <p id="paragraph-5823df738d1afc3f3150bf7502459b1e">• All authors have contributed to implementation of this research.</p>
      <p id="paragraph-ca0e7db776334787768b3e966a7532c0" />
    </sec>
    <sec id="heading-01b103fc7ad365f663fce64f314236cd">
      <title>References</title>
    </sec>
  </body>
  <back>
    <ref-list>
      <ref id="journal-article-ref-e1f020998cb8e1818fe7abc077ffd28a">
        <element-citation publication-type="journal">
          <issue>Suppl 2</issue>
          <month>07</month>
          <page-range>S78-81</page-range>
          <volume>15</volume>
          <year>2011</year>
          <pub-id pub-id-type="doi">10.4103/2230-8210.83329</pub-id>
          <person-group person-group-type="author">
            <collab>
              <named-content content-type="name">Unnikrishnan AG</named-content>
            </collab>
            <collab>
              <named-content content-type="name">Menon UV</named-content>
            </collab>
          </person-group>
          <source>Indian Journal of Endocrinology and Metabolism</source>
          <article-title>Thyroid disorders in India: An epidemiological perspective</article-title>
        </element-citation>
      </ref>
      <ref id="journal-article-ref-1acfbc635af107836449c9839c72cfca">
        <element-citation publication-type="journal">
          <page-range>17</page-range>
          <volume>2</volume>
          <year>2016</year>
          <pub-id pub-id-type="doi">10.1186/s40842-016-0035-7</pub-id>
          <person-group person-group-type="author">
            <name>
              <surname>Tamhane</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Gharib</surname>
              <given-names>H</given-names>
            </name>
          </person-group>
          <source>Clinical Diabetes and Endocrinology</source>
          <article-title>Thyroid nodule update on diagnosis and management</article-title>
        </element-citation>
      </ref>
      <ref id="journal-article-ref-c7e1fd9042eb40eff53f2aa48b30d940">
        <element-citation publication-type="journal">
          <issue>1</issue>
          <month>01</month>
          <page-range>2-8</page-range>
          <volume>15</volume>
          <year>2011</year>
          <pub-id pub-id-type="doi">10.4103/2230-8210.77566</pub-id>
          <person-group person-group-type="author">
            <name>
              <surname>Unnikrishnan</surname>
              <given-names>A. G.</given-names>
            </name>
            <name>
              <surname>Kalra</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Baruah</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Nair</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Nair</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Bantwal</surname>
              <given-names>G</given-names>
            </name>
            <collab>
              <named-content content-type="name">Sahay RK</named-content>
            </collab>
          </person-group>
          <source>Indian Journal of Endocrinology and Metabolism</source>
          <article-title>Endocrine Society of India management guidelines for patients with thyroid nodules: A position statement</article-title>
        </element-citation>
      </ref>
      <ref id="journal-article-ref-8870a5b434cb15498c649e7d56c249ed">
        <element-citation publication-type="journal">
          <article-title>NCBI Book shef. Ahmet S. Can; Anis Rehman</article-title>
        </element-citation>
      </ref>
      <ref id="journal-article-ref-b0ad99080995c6320e7edd4069534f45">
        <element-citation publication-type="journal">
          <day>01</day>
          <issue>5</issue>
          <month>05</month>
          <page-range>480-487</page-range>
          <volume>1</volume>
          <year>2017</year>
          <pub-id pub-id-type="doi">10.1210/js.2017-00097</pub-id>
          <person-group person-group-type="author">
            <collab>
              <named-content content-type="name">Mathew IE</named-content>
            </collab>
            <name>
              <surname>Mathew</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <source>Journal of the Endocrine Society</source>
          <article-title>Rising Thyroid Cancer Incidence in Southern India: An Epidemic of Overdiagnosis?</article-title>
        </element-citation>
      </ref>
      <ref id="journal-article-ref-6d09900b851e84a80a811c4554a59b76">
        <element-citation publication-type="journal">
          <day>01</day>
          <issue>3</issue>
          <month>02</month>
          <page-range>559-566</page-range>
          <volume>67</volume>
          <year>2003</year>
          <pub-id pub-id-type="doi">JJJJ</pub-id>
          <person-group person-group-type="author">
            <collab>
              <named-content content-type="name">Welker MJ</named-content>
            </collab>
            <name>
              <surname>Orlov</surname>
              <given-names>D</given-names>
            </name>
          </person-group>
          <source>American Family Physician</source>
          <article-title>Thyroid nodules</article-title>
        </element-citation>
      </ref>
      <ref id="journal-article-ref-a17958b37546548f043aa0fc2c3ea97a">
        <element-citation publication-type="journal">
          <day>01</day>
          <issue>7</issue>
          <month>07</month>
          <page-range>1284-1297</page-range>
          <volume>31</volume>
          <year>2022</year>
          <pub-id pub-id-type="doi">10.1158/1055-9965.EPI-21-1440</pub-id>
          <person-group person-group-type="author">
            <collab>
              <named-content content-type="name">Kitahara CM</named-content>
            </collab>
            <collab>
              <named-content content-type="name">Schneider AB</named-content>
            </collab>
          </person-group>
          <source>Cancer Epidemiology, Biomarkers &amp; Prevention: A Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology</source>
          <article-title>Epidemiology of Thyroid Cancer</article-title>
        </element-citation>
      </ref>
      <ref id="journal-article-ref-272aa321089c900e268f21fc34b79f70">
        <element-citation publication-type="journal">
          <issue>4</issue>
          <month>04</month>
          <page-range>264-272</page-range>
          <volume>10</volume>
          <year>2022</year>
          <pub-id pub-id-type="doi">10.1016/S2213-8587(22)00035-3</pub-id>
          <person-group person-group-type="author">
            <name>
              <surname>Pizzato</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Li</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Vignat</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Laversanne</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Singh</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>La Vecchia</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Vaccarella</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
          <source>The Lancet. Diabetes &amp; Endocrinology</source>
          <article-title>The epidemiological landscape of thyroid cancer worldwide: GLOBOCAN estimates for incidence and mortality rates in 2020</article-title>
        </element-citation>
      </ref>
      <ref id="journal-article-ref-b5cc192751fae9031ad2a57745969547">
        <element-citation publication-type="journal">
          <day>24</day>
          <issue>2</issue>
          <month>02</month>
          <page-range>e4127</page-range>
          <volume>11</volume>
          <year>2019</year>
          <pub-id pub-id-type="doi">10.7759/cureus.4127</pub-id>
          <person-group person-group-type="author">
            <name>
              <surname>Olson</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Wintheiser</surname>
              <given-names>G</given-names>
            </name>
            <collab>
              <named-content content-type="name">Wolfe KM</named-content>
            </collab>
            <name>
              <surname>Droessler</surname>
              <given-names>J</given-names>
            </name>
            <collab>
              <named-content content-type="name">Silberstein PT</named-content>
            </collab>
          </person-group>
          <source>Cureus</source>
          <article-title>Epidemiology of Thyroid Cancer: A Review of the National Cancer Database, 2000-2013</article-title>
        </element-citation>
      </ref>
      <ref id="journal-article-ref-59125bb734571a02511ac86707bc524b">
        <element-citation publication-type="journal">
          <issue>1</issue>
          <month>02</month>
          <page-range>30-40</page-range>
          <volume>8</volume>
          <year>2015</year>
          <pub-id pub-id-type="doi">HHHH</pub-id>
          <person-group person-group-type="author">
            <collab>
              <named-content content-type="name">Nguyen QT</named-content>
            </collab>
            <collab>
              <named-content content-type="name">Lee EJ</named-content>
            </collab>
            <collab>
              <named-content content-type="name">Huang MG</named-content>
            </collab>
            <collab>
              <named-content content-type="name">Park YI</named-content>
            </collab>
            <name>
              <surname>Khullar</surname>
              <given-names>A</given-names>
            </name>
            <collab>
              <named-content content-type="name">Plodkowski RA</named-content>
            </collab>
          </person-group>
          <source>American Health &amp; Drug Benefits</source>
          <article-title>Diagnosis and treatment of patients with thyroid cancer</article-title>
        </element-citation>
      </ref>
      <ref id="journal-article-ref-57741492e47db4cd15f22a19d394bb1a">
        <element-citation publication-type="journal">
          <issue>8</issue>
          <month>08</month>
          <page-range>925-951</page-range>
          <volume>20</volume>
          <year>2022</year>
          <pub-id pub-id-type="doi">10.6004/jnccn.2022.0040</pub-id>
          <person-group person-group-type="author">
            <collab>
              <named-content content-type="name">Haddad RI</named-content>
            </collab>
            <name>
              <surname>Bischoff</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Ball</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Bernet</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Blomain</surname>
              <given-names>E</given-names>
            </name>
            <collab>
              <named-content content-type="name">Busaidy NL</named-content>
            </collab>
            <name>
              <surname>Campbell</surname>
              <given-names>M</given-names>
            </name>
            <collab>
              <named-content content-type="name">et al</named-content>
            </collab>
          </person-group>
          <source>Journal of the National Comprehensive Cancer Network: JNCCN</source>
          <article-title>Thyroid Carcinoma, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology</article-title>
        </element-citation>
      </ref>
      <ref id="journal-article-ref-b64eb6604e7cef28f744a6af194d2c76">
        <element-citation publication-type="journal">
          <issue>5</issue>
          <month>10</month>
          <page-range>703-718</page-range>
          <volume>37</volume>
          <year>2022</year>
          <pub-id pub-id-type="doi">10.3803/EnM.2022.1553</pub-id>
          <person-group person-group-type="author">
            <collab>
              <named-content content-type="name">Jung CK</named-content>
            </collab>
            <name>
              <surname>Bychkov</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Kakudo</surname>
              <given-names>K</given-names>
            </name>
          </person-group>
          <source>Endocrinology and Metabolism (Seoul, Korea)</source>
          <article-title>Update from the 2022 World Health Organization Classification of Thyroid Tumors: A Standardized Diagnostic Approach</article-title>
        </element-citation>
      </ref>
      <ref id="journal-article-ref-8930a3de91fe36a7fab589ae7145a464">
        <element-citation publication-type="journal">
          <issue>6</issue>
          <month>12</month>
          <page-range>539-562</page-range>
          <volume>17</volume>
          <year>1996</year>
          <pub-id pub-id-type="doi">10.1016/s0887-2171(96)90003-7</pub-id>
          <person-group person-group-type="author">
            <name>
              <surname>Loevner</surname>
              <given-names>L. A.</given-names>
            </name>
          </person-group>
          <source>Seminars in ultrasound, CT, and MR</source>
          <article-title>Imaging of the thyroid gland</article-title>
        </element-citation>
      </ref>
      <ref id="journal-article-ref-6fbd7ceb2715a1ad4cf6a027caa8f3a7">
        <element-citation publication-type="journal">
          <issue>1</issue>
          <month>01</month>
          <page-range>1-133</page-range>
          <volume>26</volume>
          <year>2016</year>
          <pub-id pub-id-type="doi">10.1089/thy.2015.0020</pub-id>
          <person-group person-group-type="author">
            <collab>
              <named-content content-type="name">Haugen BR</named-content>
            </collab>
            <collab>
              <named-content content-type="name">Alexander EK</named-content>
            </collab>
            <collab>
              <named-content content-type="name">Bible KC</named-content>
            </collab>
            <collab>
              <named-content content-type="name">Doherty GM</named-content>
            </collab>
            <collab>
              <named-content content-type="name">Mandel SJ</named-content>
            </collab>
            <collab>
              <named-content content-type="name">Nikiforov YE</named-content>
            </collab>
            <collab>
              <named-content content-type="name">et al</named-content>
            </collab>
          </person-group>
          <source>Thyroid: Official Journal of the American Thyroid Association</source>
          <article-title>2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer</article-title>
        </element-citation>
      </ref>
      <ref id="journal-article-ref-c9320cb6f929ee2c5f5d6e2c471ddfe7">
        <element-citation publication-type="journal">
          <issue>3</issue>
          <month>06</month>
          <page-range>226-235</page-range>
          <volume>34</volume>
          <year>2013</year>
          <pub-id pub-id-type="doi">10.1053/j.sult.2012.11.001</pub-id>
          <person-group person-group-type="author">
            <collab>
              <named-content content-type="name">Patel BN</named-content>
            </collab>
            <name>
              <surname>Kamaya</surname>
              <given-names>A</given-names>
            </name>
            <collab>
              <named-content content-type="name">Desser TS</named-content>
            </collab>
          </person-group>
          <source>Seminars in ultrasound, CT, and MR</source>
          <article-title>Pitfalls in sonographic evaluation of thyroid abnormalities</article-title>
        </element-citation>
      </ref>
      <ref id="journal-article-ref-4c27c1be5507f695cd8029ba6453c452">
        <element-citation publication-type="journal">
          <day>22</day>
          <issue>2</issue>
          <month>04</month>
          <page-range>195-210</page-range>
          <volume>19</volume>
          <year>2017</year>
          <pub-id pub-id-type="doi">10.11152/mu-999</pub-id>
          <person-group person-group-type="author">
            <name>
              <surname>Dighe</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Barr</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Bojunga</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Cantisani</surname>
              <given-names>V</given-names>
            </name>
            <collab>
              <named-content content-type="name">Chammas MC</named-content>
            </collab>
            <name>
              <surname>Cosgrove</surname>
              <given-names>D</given-names>
            </name>
            <collab>
              <named-content content-type="name">Cui XW</named-content>
            </collab>
            <collab>
              <named-content content-type="name">et al</named-content>
            </collab>
          </person-group>
          <source>Medical Ultrasonography</source>
          <article-title>Thyroid Ultrasound: State of the Art. Part 2 - Focal Thyroid Lesions</article-title>
        </element-citation>
      </ref>
      <ref id="journal-article-ref-426838374d4b729ee27aea1a74e4bb09">
        <element-citation publication-type="journal">
          <issue>1</issue>
          <month>10</month>
          <page-range>156-168</page-range>
          <volume>54</volume>
          <year>2016</year>
          <pub-id pub-id-type="doi">10.1007/s12020-016-0982-x</pub-id>
          <person-group person-group-type="author">
            <name>
              <surname>Topaloglu</surname>
              <given-names>O</given-names>
            </name>
            <name>
              <surname>Baser</surname>
              <given-names>H</given-names>
            </name>
            <collab>
              <named-content content-type="name">Cuhaci FN</named-content>
            </collab>
            <name>
              <surname>Sungu</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Yalcin</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Ersoy</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Cakir</surname>
              <given-names>B</given-names>
            </name>
          </person-group>
          <source>Endocrine</source>
          <article-title>Malignancy is associated with microcalcification and higher AP/T ratio in ultrasonography, but not with Hashimoto's thyroiditis in histopathology in patients with thyroid nodules evaluated as Bethesda Category III (AUS/FLUS) in cytology</article-title>
        </element-citation>
      </ref>
      <ref id="journal-article-ref-305e533297333e545a7a94c2d342af11">
        <element-citation publication-type="journal">
          <page-range>1-15</page-range>
          <volume>45</volume>
          <year>2016</year>
          <pub-id pub-id-type="doi">10.1159/000442273</pub-id>
          <person-group person-group-type="author">
            <name>
              <surname>Andrioli</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Valcavi</surname>
              <given-names>R</given-names>
            </name>
          </person-group>
          <source>Frontiers of Hormone Research</source>
          <article-title>Sonography of Normal and Abnormal Thyroid and Parathyroid Glands</article-title>
        </element-citation>
      </ref>
      <ref id="journal-article-ref-e3cbaae48daa7fb8e9ecc8e0a97c3714">
        <element-citation publication-type="journal">
          <issue>4</issue>
          <month>04</month>
          <page-range>1253-1263</page-range>
          <volume>99</volume>
          <year>2014</year>
          <pub-id pub-id-type="doi">10.1210/jc.2013-2928</pub-id>
          <person-group person-group-type="author">
            <collab>
              <named-content content-type="name">Brito JP</named-content>
            </collab>
            <collab>
              <named-content content-type="name">Gionfriddo MR</named-content>
            </collab>
            <name>
              <surname>Al Nofal</surname>
              <given-names>A</given-names>
            </name>
            <collab>
              <named-content content-type="name">Boehmer KR</named-content>
            </collab>
            <collab>
              <named-content content-type="name">Leppin AL</named-content>
            </collab>
            <name>
              <surname>Reading</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Callstrom</surname>
              <given-names>M</given-names>
            </name>
            <collab>
              <named-content content-type="name">et al</named-content>
            </collab>
          </person-group>
          <source>The Journal of Clinical Endocrinology and Metabolism</source>
          <article-title>The accuracy of thyroid nodule ultrasound to predict thyroid cancer: systematic review and meta-analysis</article-title>
        </element-citation>
      </ref>
      <ref id="journal-article-ref-263b69c895c66203a6e84aac7e261f0f">
        <element-citation publication-type="journal">
          <issue>2</issue>
          <month>06</month>
          <page-range>305-321</page-range>
          <volume>51</volume>
          <year>2022</year>
          <pub-id pub-id-type="doi">10.1016/j.ecl.2021.12.002</pub-id>
          <person-group person-group-type="author">
            <name>
              <surname>Burgos</surname>
              <given-names>N</given-names>
            </name>
            <collab>
              <named-content content-type="name">Ospina NS</named-content>
            </collab>
            <collab>
              <named-content content-type="name">Sipos JA</named-content>
            </collab>
          </person-group>
          <source>Endocrinology and Metabolism Clinics of North America</source>
          <article-title>The Future of Thyroid Nodule Risk Stratification</article-title>
        </element-citation>
      </ref>
      <ref id="journal-article-ref-4228bf26afa3aff02092cedd2a376257">
        <element-citation publication-type="journal">
          <day>01</day>
          <issue>1</issue>
          <month>06</month>
          <page-range>35-39</page-range>
          <volume>22</volume>
          <year>2018</year>
          <pub-id pub-id-type="doi">10.5935/0946-5448.20180006</pub-id>
          <person-group person-group-type="author">
            <name>
              <surname>Kalantari</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
          <source>The International Tinnitus Journal</source>
          <article-title>The Diagnostic Value of Color Doppler Ultrasonography in Predicting Thyroid Nodules Malignancy</article-title>
        </element-citation>
      </ref>
      <ref id="journal-article-ref-2b9a0bf2f083d2971349cf681388a6cd">
        <element-citation publication-type="journal">
          <issue>8</issue>
          <month>08</month>
          <page-range>TC01-06</page-range>
          <volume>10</volume>
          <year>2016</year>
          <pub-id pub-id-type="doi">10.7860/JCDR/2016/18459.8227</pub-id>
          <person-group person-group-type="author">
            <collab>
              <named-content content-type="name">Palaniappan MK</named-content>
            </collab>
            <collab>
              <named-content content-type="name">Aiyappan SK</named-content>
            </collab>
            <name>
              <surname>Ranga</surname>
              <given-names>U</given-names>
            </name>
          </person-group>
          <source>Journal of clinical and diagnostic research: JCDR</source>
          <article-title>Role of Gray Scale, Color Doppler and Spectral Doppler in Differentiation Between Malignant and Benign Thyroid Nodules</article-title>
        </element-citation>
      </ref>
    </ref-list>
  </back>
</article>